Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. N-((3-(2-fluoro-4'-(((1h-1,2,3-triazol-5-ylmethyl)amino)methyl)(1,1'-biphenyl)-4-yl)-2-oxo-5-oxazolidinyl)methyl)acetamide
2. Rx 1741
3. Rx-1741
4. Rx1741
1. 869884-78-6
2. Rx-1741
3. Rx-103
4. N-[[(5s)-3-[2-fluoro-4'-[[(1h-1,2,3-triazol-5-ylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]acetamide
5. Rx103
6. Rx-01_667
7. 53pc6lo35w
8. Mmv688327
9. Rx-013
10. Rx1741
11. (s)-n-((3-(4'-((((1h-1,2,3-triazol-5-yl)methyl)amino)methyl)-2-fluoro-[1,1'-biphenyl]-4-yl)-2-oxooxazolidin-5-yl)methyl)acetamide
12. N-[[(5s)-3-[3-fluoro-4-[4-[(2h-triazol-4-ylmethylamino)methyl]phenyl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
13. N-{[(5s)-3-(2-fluoro-4'-{[(1h-1,2,3-triazol-5-ylmethyl)amino]methyl}biphenyl-4-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
14. Radezolid [usan]
15. And Rx-01_667
16. Rx-o1_667
17. Radezolid [usan:inn]
18. Unii-53pc6lo35w
19. Rx 1741
20. (5s)-n-[3-(2-fluoro-4'-{[(1h-[1,2,3]triazol-4-ylmethyl)-amino]-methyl)-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide
21. (5s)-n-[3-(2-fluoro-4'-{[(1h-[1,2,3]triazol-4-ylmethyl)-amino]-methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide
22. N-(((5s)-3-(2-fluoro-4'-(((1h-1,2,3-triazol-5-ylmethyl)amino)methyl)biphenyl-4-yl)-2-oxo-1,3-oxazolidin-5-yl)methyl)acetamide
23. Rd8
24. Radezolid [inn]
25. Radezolid (usan/inn)
26. Radezolid [who-dd]
27. Chembl455461
28. Schembl1035776
29. Schembl10109382
30. Gtpl10849
31. Dtxsid301007238
32. Ex-a1247
33. Zinc40379938
34. Cs-0688
35. Db12339
36. Rx-01-667
37. Ac-36840
38. Hy-14800
39. D09369
40. A902025
41. Q7280139
42. Acetamide, N-(((5s)-3-(2-fluoro-4'-(((1h-1,2,3-triazol-5-ylmethyl)amino)methyl)(1,1'-biphenyl)-4-yl)-2-oxo-5-oxazolidinyl)methyl)-
43. N-((3-(2-fluoro-4'-(((1h-1,2,3-triazol-5-ylmethyl)amino)methyl)(1,1'-biphenyl)-4-yl)-2-oxo-5-oxazolidinyl)methyl)acetamide
44. N-({(5s)-3-[2-fluoro-4'-({[(1h-1,2,3-triazol-4-yl)methyl]amino}methyl)[1,1'-biphenyl]-4-yl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide
45. N-[[(5s)-3-[3-fluoro-4-[4-[(1h-triazol-5-ylmethylamino)methyl]phenyl]phenyl]-2-oxo-oxazolidin-5-yl]methyl]acetamide
46. N-{ [(5s)-3-(2-fluoro-4'-{[(1h-1,2,3-triazol-5-ylmethyl)amino]methyl}biphenyl-4-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
| Molecular Weight | 438.5 g/mol |
|---|---|
| Molecular Formula | C22H23FN6O3 |
| XLogP3 | 1.1 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 8 |
| Exact Mass | 438.18156678 g/mol |
| Monoisotopic Mass | 438.18156678 g/mol |
| Topological Polar Surface Area | 112 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 647 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
ABOUT THIS PAGE
95
PharmaCompass offers a list of RX-1741 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right RX-1741 manufacturer or RX-1741 supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred RX-1741 manufacturer or RX-1741 supplier.
PharmaCompass also assists you with knowing the RX-1741 API Price utilized in the formulation of products. RX-1741 API Price is not always fixed or binding as the RX-1741 Price is obtained through a variety of data sources. The RX-1741 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A RX 1741 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of RX 1741, including repackagers and relabelers. The FDA regulates RX 1741 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. RX 1741 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A RX 1741 supplier is an individual or a company that provides RX 1741 active pharmaceutical ingredient (API) or RX 1741 finished formulations upon request. The RX 1741 suppliers may include RX 1741 API manufacturers, exporters, distributors and traders.
RX 1741 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of RX 1741 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right RX 1741 GMP manufacturer or RX 1741 GMP API supplier for your needs.
A RX 1741 CoA (Certificate of Analysis) is a formal document that attests to RX 1741's compliance with RX 1741 specifications and serves as a tool for batch-level quality control.
RX 1741 CoA mostly includes findings from lab analyses of a specific batch. For each RX 1741 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
RX 1741 may be tested according to a variety of international standards, such as European Pharmacopoeia (RX 1741 EP), RX 1741 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (RX 1741 USP).
